Cepheid, an operating company within Danaher (NYSE:DHR), has announced the development of a next-generation test to assist global efforts in the fight against the spread of COVID-19.
The Xpert Xpress SARS-CoV-2/Flu/RSV four-in-one
test is expected to deliver qualitative detection of SARS-CoV-2, Flu A,
Flu B and RSV from a single patient sample.
The test is designed for use on any of Cepheid’s
more than 25,000 GeneXpert Systems placed worldwide, with results
expected in as little as 35 minutes.
https://seekingalpha.com/news/3581439-four-in-one-test-for-covidminus-19-flu-rsv
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.